C&R Research Inc. (KOSDAQ:359090)
South Korea · Delayed Price · Currency is KRW 2,245.00
+10.00 (0.45%)
At close: Oct 23, 2026
C&R Research Revenue
C&R Research had revenue of 17.78B KRW in the quarter ending June 30, 2026, with 5.01% growth. This brings the company's total for the last twelve months to 63.55B, down -1.69% year-over-year. In the year 2025, C&R Research had annual revenue of 64.98B with 8.87% growth. That makes C&R Research the 28,240th largest company in the world by revenue and 1,723rd in South Korea.
Revenue (ttm)
63.55B
Revenue Growth
-1.69%
P/S Ratio
0.41
Revenue / Employee
130.76M
Employees
486
Market Cap
25.80B
Revenue by Geography
- South Korea 63.80B 98.2%
- Overseas 1.18B 1.8%
Fiscal year ended Dec 31, 2025 See the full C&R Research breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 64.98B | 5.29B | 8.87% |
| Dec 31, 2024 | 59.69B | 4.59B | 8.32% |
| Dec 31, 2023 | 55.10B | 6.63B | 13.68% |
| Dec 31, 2022 | 48.47B | 5.30B | 12.28% |
| Dec 31, 2021 | 43.17B | 15.97B | 58.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DreamCIS | 73.28B |
| HLB bioStep | 72.15B |
| DT&CRO CO. | 49.00B |
| Kolmar BioTech | 40.30B |
| BioInfra | 25.62B |
| P&K Skin Research Center | 23.67B |
| Penetrium Bioscience | 9.74B |
| Curachem | 6.02B |